In vivo CRISPR therapy successfully reduces hereditary angioedema attacks in first Phase III trial

Researchers from Amsterdam UMC, in collaboration with other hospitals, have successfully completed the first Phase III study of an in vivo CRISPR therapy.

In this large-scale, double-blind trial, 80 patients with hereditary angioedema were randomized to receive either the CRISPR therapy or a placebo.

CRISPR therapy is a medical technique that allows doctors to precisely modify errors in cellular DNA to treat specific hereditary diseases. ...